Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
OBJECTIVE
To assess the direct medical costs and cost effectiveness of routine eptifibatide use amongst patients with unstable angina and myocardial infarction without persistent ST-segment elevation in the Western European subgroup of the PURSUIT trial.


RESULTS
Health care resources were collected for the Western European PURSUIT trial patients (n=3697). Unit costs for major resources were developed within six countries using a consistent bottom-up methodology. Resource consumption from the Western European population was used to calculate the average direct medical costs per patient in the eptifibatide and placebo arms of the trial. Eptifibatide was estimated to cost 524 Euros per treatment. Long-term survival estimated from the 6-month trial survival data and combined with the cost data was used to calculate cost-effectiveness ratios. Additionally, cost per death and non-fatal myocardial infarction at 30 days was calculated. Sensitivity analyses were conducted on the discount rate and resource consumption. Cost-effectiveness ratios ranged from 9603 Euros to 18 115 Euros per year of life saved with 3% discount. Using resource consumption based on countries with low coronary arteriography rates, the cost per year of life saved was between 3329 Euros and 10 079 Euros. Using resource consumption based on high coronary arteriography rate countries, the cost per year of life saved was between 17 089 Euros and 24 099 Euros. Assuming no difference in treatment costs except for the addition of eptifibatide, the incremental cost per year of life saved was 23 818 Euros.


CONCLUSIONS
Routine eptifibatide use was associated with a reduction in the combined end-point of death and myocardial infarction at 30 days, which was sustained at 6 months. Long-term projections indicate a modest increase in survival in eptifibatide patients. These data translate into cost-effectiveness ratios that compare favourably with other new technologies that are currently in use.
Brown
R E
RE
MEDTAP International Inc, London, U.K.
Henderson
R A
RA
Koster
D
D
Hutton
J
J
Simoons
M L
ML
D000208:Acute Disease; D000368:Aged; D001026:Coronary Artery Bypass / Q000191:economics; D003327:Coronary Disease / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000191:economics; D003935:Diagnostic Techniques, Cardiovascular / Q000191:economics; D023381:Endpoint Determination; D000077542:Eptifibatide; D005060:Europe / Q000453:epidemiology; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000191:economics / Q000601:surgery; D010343:Patient Admission / Q000191:economics; D010455:Peptides / Q000191:economics* / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013577:Syndrome; D016896:Treatment Outcome
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide